Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-07-01
2000-06-27
Crane, L. Eric
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 48, 514 50, 514 51, 536 2623, 424417, A61K 3170
Patent
active
060807318
ABSTRACT:
5',5'-Pyrophosphates of non-naturally occurring nucleosides selected from thymine-3'-azido-2',3'-dideoxy-D-riboside, 5-fluorouracil-2'-deoxy-D-riboside, uracil-3'-azido-2',3'-dideoxy-D-riboside, guanine-2',3'-dideoxy-D-riboside, hypoxanthing-2',3'-dideoxy-D-riboside, cytosine-2',3'-dideoxy-D-riboside, and adenine-2',3'-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutical pharmaceutical compositions or as pro-drugs encapsulated into biological carriers, e.g., transformed erythrocytes, for targeting to specific cell population responsible of the development of the pathological disorders.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt
patent: 3506478 (1970-04-01), Myers
patent: 4855304 (1989-08-01), Devash
patent: 5159067 (1992-10-01), Schinazi et al.
patent: 5521161 (1996-05-01), Malley et al.
Tonetti et al., "Liver Targetting of Autologous Erythrocytes Loaded with Doxorubicin," European J. Cancer, 27(7), 947-948 (Jul. 1991).
DeFlora et al., "Engineered Erythorcytes as Carriers and Bioreactors," in Generation of Antibodies by Cell and Cell Immortalization, The Year in Immunology, vol. 7, Terhorst et al. (eds.), Karger, New York, NY, 1993, pp. 168-174.
Hagemeier et al., "High-Performance Liquid Chromatographic Methods for Separation of Dinucleotides," J. Chromatography, 237(1), 174-177 (Mar. 5, 1982).
Iwase et al., "Molecular Design of a Eukaryotic Messenger RNA and Its Chemical Synthesis," Nucleic Acids Res., 20(7), 1643-1648 (Apr. 11, 1992).
Bornemann et al., "Darstellung 5', 5"-Phosphatverknupfter Dinucleoside," Z. Naturforschung, 36c(1/2), 135-141 (Jan./Feb., 1981).
Magnani et al., "Synthesis and Targeted Delivery of an Azidothymidine Homodinucleotide Conferring Protection to Macrophages Against Retroviral Infection," Proc. Nat. Acad. Sci. USA, 93(9), 4403-4408 (Apr. 30, 1996).
Benatti et al., "Azidothymidine Homodinucleotide-Loaded Erythrocytes as Bioreactors for Slow Delivery of the Antiretroviral Drug Azidothymidine," Biomedical Biophysical Res. Comm., 220(1), 20-25 (Mar. 7, 1996).
Michelson et al., "Synthesis of Nucleoside Anhydrides by Anion Exchange," Biochem. Biophys. Acta, 91(1), 1-13 (Sep. 11, 1964).
Mosier et al., "Functional T Lymphocytes Are Required for a Murine Retrovirus-Induced Immunodeficiency Disease (MAIDS)," Journal fo Experimen tal Medicine, 165(6), 1737-1742 (Jun. 1, 1987).
Robbins e al., "Enzymatic Assay for Measurement of Zidovudine Triphosphate in Peripheral Blood Mononuclear Cells," Antimicrobial Agents and Chemotherapy, 38(1), 15-121 (Jan. 1994).
Schinazi et al., "Activities of 3'-Azido-3'-deoxythymidine Nucleotide Dimers in Primary Lymphocytes Infected with Human Immunodeficiency Viruus Type 1," Antimicrobial Agents and Chemotherapy, 34(6), 1061-1067 (Jun., 1990).
Puesch et al., "Synthesis and Biological Evaluation of Dinucleoside Methylphosphonates of 3'-Azido-3'-deoxythymidine and 2',3'-Dideoxycytidine," Antiviral Research, 12, 11-23 (1990).
Benatti Umberto
De Flora Antonio
Giovine Marco
Biosearch Italia S.p.A.
Crane L. Eric
University of Genoa
LandOfFree
Dinucleoside-5', 5'-pyrophosphates administered to treat HIV does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dinucleoside-5', 5'-pyrophosphates administered to treat HIV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dinucleoside-5', 5'-pyrophosphates administered to treat HIV will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1784860